New Launch27 March 2026 at 03:51 pm
Sun Pharma Showcases Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
AI Summary
Sun Pharmaceutical Industries Limited (Sun Pharma) is set to present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, highlighting its expertise and commitment in dermatology and immunology. The data includes findings on ILUMYA® for psoriasis, LEQSELVI™ for alopecia areata, and WINLEVI® for acne, demonstrating sustained efficacy, significant hair regrowth, and reduction in acne severity respectively. The company also emphasizes its commitment to patient-centered care and real-world evidence.
Key Highlights
- Sun Pharma to present 14 abstracts at 2026 AAD Annual Meeting
- Data underscores category leadership and expertise in dermatology and immunology
- ILUMYA® shows sustained efficacy and safety in psoriasis affecting the nails
- LEQSELVI™ demonstrates significant scalp hair regrowth in alopecia areata
- WINLEVI® shows significant and progressive reduction in acne severity